Page 156 - 《南京医科大学学报（自然科学版）》2026年第3期

第46卷第3期
·464 · 南 京 医 科 大 学 学 报 2026年3月

ian latent class model for the diagnostic performance of plasma p⁃tau217：performance in individuals with subjec⁃
mini ⁃ mental state examination and Montreal cognitive tive cognitive decline and early Alzheimer’s disease［J］.
assessment in screening mild cognitive impairment due to Alzheimers Dement，2024，20（2）：1239-1249
Alzheimer’s disease［J］. J Prev Alzheimers Dis，2022，9 ［21］VANDEVREDE L，LA JOIE R，THIJSSEN E H，et al.
（4）：589-600 Evaluation of plasma phosphorylated Tau217 for differen⁃
［9］ DARK H E，AN Y，DUGGAN M R，et al. Alzheimer’s tiation between Alzheimer disease and frontotemporal
and neurodegenerative disease biomarkers in blood pre⁃ lobar degeneration subtypes among patients with cortico⁃
dict brain atrophy and cognitive decline［J］. Alzheimers basal syndrome［J］. JAMA Neurol，2023，80（5）：495
Res Ther，2024，16（1）：94 ［22］OECKL P，OTTO M. A review on MS ⁃ based blood bio⁃
［10］RICHARDS D，SABBAGH M N. Florbetaben for PET ima⁃ markers for Alzheimer’s disease［J］. Neurol Ther，2019，8
ging of beta ⁃ amyloid plaques in the brain［J］. Neurol （2）：113-127
Ther，2014，3（2）：79-88 ［23］GARCIA⁃ESCOBAR G，MANERO R M，FERNÁNDEZ⁃
［11］OSSENKOPPELE R，VAN DER KANT R，HANSSON O. LEBRERO A，et al. Blood biomarkers of Alzheimer’s
Tau biomarkers in Alzheimer’s disease：towards imple⁃ disease and cognition：a literature review［J］. Biomole⁃
mentation in clinical practice and trials［J］. Lancet Neu⁃ cules，2024，14（1）：93
rol，2022，21（8）：726-734 ［24］CUI Y Y，ZHANG H K，ZHU J，et al. Investigation of
［12］BONOMI S，GUPTA M R，SCHINDLER S E. Inadequate whole and glandular saliva as a biomarker for Alzheimer’s
reimbursement for lumbar puncture is a potential barrier disease diagnosis［J］. Brain Sci，2022，12（5）：595
to accessing new Alzheimer’s disease treatments［J］. ［25］PICHET BINETTE A，MAMMANA A，WISSE L，et al.
Alzheimers Dement，2023，19（12）：5849-5851 Associations between misfolded alpha ⁃ synuclein aggre⁃
［13］PALMQVIST S，JANELIDZE S，QUIROZ Y T，et al. Dis⁃ gates and Alzheimer ’s disease pathology in vivo［J］.
criminative accuracy of plasma phospho ⁃ tau217 for Alzheimers Dement，2024，20（11）：7624-7634
Alzheimer disease vs other neurodegenerative disorders［J］. ［26］HANSSON O. Biomarkers for neurodegenerative disea⁃
Jama，2020，324（8）：772 ses［J］. Nat Med，2021，27（6）：954-963
［14］CHAPPELLE S D，GIGLIOTTI C，LEGER G C，et al. ［27］LEE M，GUO J⁃P，KENNEDY K，et al. A method for diag⁃
Comparison of the telephone ⁃ Montreal cognitive assess⁃ nosing Alzheimer’s disease based on salivary amyloid⁃β
ment（T⁃MoCA）and telephone interview for cognitive sta⁃ protein 42 levels［J］. J Alzheimers Dis，2016，55（3）：
tus（TICS）as remote screening tests for early Alzheimer’ 1175-1182
s disease［J］. Alzheimers Dement，2022，18（S7）： ［28］HEATHER P，QURESHI H Y，PAUDEL H K，et al. Develo⁃
e065917 pment and validation of a salivary tau biomarker in
［15］HAMPEL H，AU R，MATTKE S，et al. Designing the next⁃ Alzheimer’s disease［J］. Alzheimers Dementi（Amst），
generation clinical care pathway for Alzheimer’s dis⁃ 2019，11：53-60
ease［J］. Nat Aging，2022，2（8）：692-703 ［29］CARRO E，BARTOLOMÉ F，BERMEJO⁃PAREJA F，et
［16］PETERSEN R C，GRAF A，BRADY C，et al. Operational⁃ al. Early diagnosis of mild cognitive impairment and
izing selection criteria for clinical trials in Alzheimer’s Alzheimer’s disease based on salivary lactoferrin［J］.
disease：biomarker and clinical considerations［J］. A&D Alzheimers Dement（Amst），2017，8（1）：131-138
Transl Res Clin Interv，2023，9（4）：e12434 ［30］NIJAKOWSKI K，OWECKI W，JANKOWSKI J，et al. Sali⁃
［17］NEAL S J，CHITTA S，MAGDEN E R，et al. Characteriz⁃ vary biomarkers for Alzheimer’s disease：a systematic
ing plasma and cerebrospinal fluid biomarkers relevant to review with meta⁃analysis［J］. Int J Mol Sci，2024，25（2）：
neurodegeneration in captive olive baboons （Papio 1168
anubis）［J］. PLoS One，2025，20（2）：e0318173 ［31］QUARESIMA V，PILOTTO A，TRASCIATTI C，et al. Plas⁃
［18］DELABY C，HIRTZ C，LEHMANN S. Overview of the ma p ⁃ tau181 and amyloid markers in Alzheimer’s dis⁃
blood biomarkers in Alzheimer’s disease：promises and ease：a comparison between lumipulse and SIMOA［J］.
challenges［J］. Rev Neurol，2023，179（3）：161-172 Neurobiol Aging，2024，143：30-40
［19］MANDAL P K，MAROON J C，GARG A，et al. Blood bio⁃ ［32］GONZÁLEZ ⁃ SÁNCHEZ M，BARTOLOME F，ANTE⁃
markers in Alzheimer’s disease［J］. ACS Chem Neurosci， QUERA D，et al. Decreased salivary lactoferrin levels are
2023，14（22）：3975-3978 specific to Alzheimer’s disease［J］. EBioMedicine，2020，
［20］GONZALEZ⁃ORTIZ F，FERREIRA P C L，GONZÁLEZ⁃ 57：102834
ESCALANTE A，et al. A novel ultrasensitive assay for ［33］YILMAZ A，GEDDES T，HAN B，et al. Diagnostic bio⁃